Dyne Therapeutics (DYN) Expands Term Loan Facility with Hercules Capital by $400M to Advance Clinical Pipeline

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the best upside stocks to buy according to hedge funds. On June 17, Dyne Therapeutics expanded its senior secured term loan facility with Hercules Capital to up to $400 million, increasing financial flexibility. This amendment includes an immediate $50 million funding and provides additional tranches tied to specific clinical and regulatory milestones. These funds will support the advancement of the company’s lead candidates, z-rostudirsen for Duchenne muscular dystrophy and z-basivarsen for myotonic dystrophy type 1.

The expanded partnership strengthens Dyne’s balance sheet as it prepares for two potential US commercial launches over the next two years. By securing non-dilutive capital, the company aims to maintain momentum in its mission to deliver functional improvements for patients with rare neuromuscular diseases. The agreement reflects Hercules Capital’s continued support for Dyne’s clinical progress and transformative development stage.

To date, Dyne Therapeutics Inc. (NASDAQ:DYN) has borrowed a total of $200 million under the facility and maintains access to an additional $200 million in potential future funding. This arrangement provides the capital necessary to reach key milestones while optimizing the company’s financial position. The collaboration highlights a shared commitment to accelerating the delivery of innovative treatments to patients in need.

Dyne Therapeutics (DYN) Expands Term Loan Facility with Hercules Capital by $400M to Advance Clinical Pipeline

Dyne Therapeutics Inc. (NASDAQ:DYN) engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.

While we acknowledge the risk and potential of DYN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DYN and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1